Vima LLC’s Indivior Pharmaceuticals INDV Stock Holding History

Vima LLC’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-50	Closed	-$764	–	473
2023 Q4	$764	Buy	+50	New	+$888	﹤0.01%	362

Other funds holding INDV

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Vima LLC's INDV Position: Q1 2024 in Review

Vima LLC sold out of Indivior Pharmaceuticals (INDV) in Q1 2024, closing a stake of 50 shares — an estimated $764 sold.

Vima LLC first reported a position in INDV in Q4 2023 and held it in 1 quarter. The position peaked at $764 in Q4 2023. 95 funds tracked by Wall St. Rank hold INDV as of Q1 2024.

Vima LLC reported no remaining Indivior Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Vima LLC sold 50 Indivior Pharmaceuticals shares in Q1 2024, an estimated $764.
Vima LLC first reported a position in Indivior Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Vima LLC's Indivior Pharmaceuticals position peaked at $764 in Q4 2023.
95 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2024.

Based on Vima LLC's 13F filing for Q1 2024, filed 17 May 2024.